Insulet Co. (NASDAQ:PODD) Shares Sold by Two Sigma Investments LP

Two Sigma Investments LP lessened its holdings in Insulet Co. (NASDAQ:PODD - Free Report) by 56.6% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 16,978 shares of the medical instruments supplier's stock after selling 22,134 shares during the quarter. Two Sigma Investments LP's holdings in Insulet were worth $4,432,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Horizon Investments LLC grew its holdings in shares of Insulet by 3.1% in the fourth quarter. Horizon Investments LLC now owns 1,387 shares of the medical instruments supplier's stock worth $362,000 after purchasing an additional 42 shares during the last quarter. Nisa Investment Advisors LLC boosted its position in Insulet by 1.0% in the 4th quarter. Nisa Investment Advisors LLC now owns 4,388 shares of the medical instruments supplier's stock valued at $1,146,000 after buying an additional 43 shares during the period. Wilmington Savings Fund Society FSB grew its stake in Insulet by 9.6% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 538 shares of the medical instruments supplier's stock worth $140,000 after acquiring an additional 47 shares in the last quarter. Envestnet Portfolio Solutions Inc. increased its position in shares of Insulet by 2.3% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 2,113 shares of the medical instruments supplier's stock worth $552,000 after acquiring an additional 48 shares during the period. Finally, Steward Partners Investment Advisory LLC raised its stake in shares of Insulet by 5.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,050 shares of the medical instruments supplier's stock valued at $274,000 after acquiring an additional 50 shares in the last quarter.

Insulet Stock Up 0.2%

PODD traded up $0.65 during trading on Friday, hitting $324.50. The stock had a trading volume of 960,683 shares, compared to its average volume of 706,851. The stock has a 50 day simple moving average of $276.61 and a two-hundred day simple moving average of $271.78. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. Insulet Co. has a twelve month low of $172.07 and a twelve month high of $329.33. The company has a market capitalization of $22.84 billion, a PE ratio of 56.05, a PEG ratio of 3.62 and a beta of 1.26.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, topping analysts' consensus estimates of $0.81 by $0.21. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The firm had revenue of $569.00 million during the quarter, compared to analysts' expectations of $543.20 million. During the same quarter last year, the firm earned $0.73 EPS. The business's quarterly revenue was up 28.8% on a year-over-year basis. On average, research analysts predict that Insulet Co. will post 3.92 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Wayne A.I. Frederick sold 1,825 shares of the firm's stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total value of $501,875.00. Following the completion of the transaction, the director now directly owns 3,231 shares in the company, valued at $888,525. This trade represents a 36.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP John W. Kapples sold 5,278 shares of Insulet stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total value of $1,680,884.66. Following the sale, the senior vice president now directly owns 23,180 shares of the company's stock, valued at $7,382,134.60. This trade represents a 18.55% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.39% of the company's stock.

Wall Street Analyst Weigh In

PODD has been the topic of several research analyst reports. Wells Fargo & Company set a $322.00 price objective on Insulet in a research note on Monday, April 28th. The Goldman Sachs Group began coverage on Insulet in a report on Friday. They issued a "buy" rating and a $380.00 target price for the company. Wolfe Research upgraded Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 price target on the stock in a research note on Tuesday, May 13th. Barclays lifted their price objective on Insulet from $234.00 to $266.00 and gave the company an "equal weight" rating in a report on Wednesday, April 30th. Finally, Citigroup reiterated a "buy" rating and set a $380.00 target price (up from $320.00) on shares of Insulet in a report on Thursday, May 22nd. Three investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Insulet presently has an average rating of "Moderate Buy" and a consensus target price of $318.41.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.